What is the efficacy of chemotherapy in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

A phase II trial of weekly intravenous (IV) gemcitabine (600 mg/m2 on days 1, 8, and 15) with continuous infusion 5-FU (150 mg/m2/d for 21 days in a 28-day cycle) in patients with metastatic RCC produced a partial response rate of 17%. [65] No complete responses were noted. Eighty percent of patients had multiple metastases, and 83% had received previous treatment. The mean progression-free survival duration of 28.7 weeks was significantly longer than that of historic controls. [65]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!